INDEX OF AUTHORS

Abelson, N. M., 391 Abramson, J. H., 153 Adler, E., 153 Aliferis, P., 521 Arterberry, J. D., 138 Aviad, I., 228

Bayles, T. B., 103 Bender, L. F., 467 Borges, W. H., 448 Blumberg, B. S., 93 Brown, R. R., 201 Brunjes, S., 138 Bunim, J. J., 93

Calabro, J. J., 425 Calkins, E., 8, 93, 272 Casals, S. P., 379 Chrisman, O. D., 398 Christian, C. L., 455 Clifford, G. O., 443 Cloud, S., 654 Cohen, A. S., 8, 490 Curry, N., 513

Decker, J. L., 177 Denko, C. W., 99 Davidson, P., 406

Eakin, L., 75 Edwards, M. H., 425 Elkan, Z., 153 Engleman, E. P., 278, 406 Evans, H. W., 51 Eyquem, A., 110

Fessel, J. M., 398 Fisher, D. A., 413 Flinn, J. H., 201 Ford, D. K., 185, 220 Fremont-Smith, K., 103 Friou, G. J., 161, 379

Gabriel, K. R., 153 Gardner, F. H., 278 Gerber, D. A., 193 Gonzales-Alcover, R., 171 Good, A. E., 56, 65

Hador, S. B., 153 Hartung, E. F., 167 Healey, L. A., 275 Herd, K., 259 Hogan, J. M., 359 Holborow, J., 119 Holley, H. L., 684 Hong, R., 128 Hsu, J. M., 636

Jacox, R. F., 481 Jacqueline, F., 110 Johns, V. J., 138 Johnson, G. D., 119 Johnson, L. C., 714 Jones, L. G., 636 Jones, R. S., 654 Juvinall, R. C., 467

Krawitt, E. L., 654

Lever, W., 186 Loeb, H. G., 723 Loza, U., 1

Martel, W., 714
McCarty, D. J., Jr., 359, 534, 709
McDuffle, F. C., 87
McEwen, C., 542, 623
McKusick, A. B., 636
Melby, J. C., 413
Mendez-Bryan, R., 171
Milgrom, F., 1
Mongan, E. S., 481
Murray, D. G., 211
Myers, L. L., 379

Nalven, F. B., 18 Nathan, H., 228 Nesterov, A. I., 29

O'Brien, J. F., 18 Oesterreicher, W., 670 Olitzky, I., 723

Panos, T. C., 413 Pearson, C. M., 80, 278 Pearson, J. R., 467 Pinals, R. S., 241, 662 Pirani, C. L., 93, 448 Podliachouk, L., 110 Price, J. M., 201

Ragan, C., 187 Rasmussen, G., 220 Rawson, A. J., 391 Robin, G. C., 228 Rodnan, G. P., 75 Roger, L., 171 Ropes, M. W., 241 Rosenthal, A. S., 502

INDEX OF AUTHORS

Abelson, N. M., 391 Abramson, J. H., 153 Adler, E., 153 Aliferis, P., 521 Arterberry, J. D., 138 Aviad, I., 228

Bayles, T. B., 103 Bender, L. F., 467 Borges, W. H., 448 Blumberg, B. S., 93 Brown, R. R., 201 Brunjes, S., 138 Bunim, J. J., 93

Calabro, J. J., 425 Calkins, E., 8, 93, 272 Casals, S. P., 379 Chrisman, O. D., 398 Christian, C. L., 455 Clifford, G. O., 443 Cloud, S., 654 Cohen, A. S., 8, 490 Curry, N., 513

Decker, J. L., 177 Denko, C. W., 99 Davidson, P., 406

Eakin, L., 75 Edwards, M. H., 425 Elkan, Z., 153 Engleman, E. P., 278, 406 Evans, H. W., 51 Eyquem, A., 110

Fessel, J. M., 398 Fisher, D. A., 413 Flinn, J. H., 201 Ford, D. K., 185, 220 Fremont-Smith, K., 103 Friou, G. J., 161, 379

Gabriel, K. R., 153 Gardner, F. H., 278 Gerber, D. A., 193 Gonzales-Alcover, R., 171 Good, A. E., 56, 65

Hador, S. B., 153 Hartung, E. F., 167 Healey, L. A., 275 Herd, K., 259 Hogan, J. M., 359 Holborow, J., 119 Holley, H. L., 684 Hong, R., 128 Hsu, J. M., 636

Jacox, R. F., 481 Jacqueline, F., 110 Johns, V. J., 138 Johnson, G. D., 119 Johnson, L. C., 714 Jones, L. G., 636 Jones, R. S., 654 Juvinall, R. C., 467

Krawitt, E. L., 654

Lever, W., 186 Loeb, H. G., 723 Loza, U., 1

Martel, W., 714
McCarty, D. J., Jr., 359, 534, 709
McDuffle, F. C., 87
McEwen, C., 542, 623
McKusick, A. B., 636
Melby, J. C., 413
Mendez-Bryan, R., 171
Milgrom, F., 1
Mongan, E. S., 481
Murray, D. G., 211
Myers, L. L., 379

Nalven, F. B., 18 Nathan, H., 228 Nesterov, A. I., 29

O'Brien, J. F., 18 Oesterreicher, W., 670 Olitzky, I., 723

Panos, T. C., 413 Pearson, C. M., 80, 278 Pearson, J. R., 467 Pinals, R. S., 241, 662 Pirani, C. L., 93, 448 Podliachouk, L., 110 Price, J. M., 201

Ragan, C., 187 Rasmussen, G., 220 Rawson, A. J., 391 Robin, G. C., 228 Rodnan, G. P., 75 Roger, L., 171 Ropes, M. W., 241 Rosenthal, A. S., 502 Rosenthal, R. K., 103 Rubin, P., 693 Ruderman, M., 709 Ruhl, M. J., 615

Schubart, A. F., 8 Schumacher, H. R., Jr., 41 Shalit, I. E., 177 Shankel, S., 138 Sharp, J. T., 437 Sherwin, R. W., 636 Smith, E. M., 467 Smyth, C. J., 687, 714 Sokoloff, L., 615 Staub, A., 687

Thomison, J. B., 502 Thompson, G. R., 521 Tonder, O., 1 Toone, E., 448 Toone, E. C., 513

van Dam, G., 670 Vaughan, E., 513 Vaughan, J. H., 259

Wahl, M., 153
Waller, M., 513
Ward, J. R., 654
Weinberg, H., 228
West, C. D., 128
Wied, M. E., 425
Williams, R. C., Jr., 368
Wilske, K. R., 177
Wilson, F. M., 443
Wolf, P. L., 443

Yess, N., 201

Zvaifler, 93

INDEX OF SUBJECTS

(Page numbers in italics refer to abstracts)

Acetylsalicylic acid esterase in aspirin metabolism, 350

Achondroplasia, 695-702

Acid phosphatase, and antibody effects on tissue culture cells, 323

Acromegalic arthropathy, 65-73

Adenosine nucleotides in platelets, metabolism of, 741

Adjuvant arthritis

estrogen suppression of, 333

induction procedure, 742

inhibition by protein antigens, 337

latent stage of, 316

polyarthritis and immune response, 654-661

and subfractions of Wax D, 746

Adrenal steroid therapy. See Steroid therapy Agammaglobulinemia, 309

Agglutinating factors eluted from erythrocytes, in rheumatoid arthritis, 739

Agglutinins, anti-Gm. See Anti-Gm substances

Aging

and protein synthesis in articular cartilage, 743

serologic reactions and serum proteins in, 297 in tendons, 733 Albumin alterat bovine

alterations in rheumatic disease, 747 bovine serum, denaturation of, chloroquine affecting, 193–199

hypoalbuminemia in rheumatoid arthritis, 740 Aldehydes, effect on tensile strength of skin

collagen, 330 Aleutian mink disease, 521–533

Allopurinol, effects on uric acid excretion,

American Rheumatism Association annual meeting of 1964, 189, 452

proceedings of, 284–355 Arthritis Foundation, 762

Clark named Foundation president, 547 Conference on Gout and Purine Metabolism, 100-101, 452

criteria for diagnosis of rheumatoid arthritis, 745

death of Dr. Bunim, 452, 542-544

Gairdner Foundation Awards, 101 Index of Rheumatology, 618-619, 762

interim session of 1963, 100

interim session of 1964, 452, 547

proceedings of, 724–761 International Gout Congress, 101 literature analysis project, 615–622 American Rheumatism-(Continued) new directory available, 548 New York Rheumatism Association, 167-

news from Europe, 190

e Theseures nomenclature and classification in, 93-96 ussue & well Polley installed as President, 451 xes) workshop on June 17, 189

Amine metabolism, in scleroderma, 138-149 Amino acids, and hyperuricemia, 319 Amopyroquin, in rheumatoid disease, 289 Amyloid

anti-amyloid antibodies, 299 association with gamma globulin, 751 isolation and characterization of, 338 production of, by tissue explants, 301

Amyloidosis, pathogenesis of, 284 Analgesics, oral, computer program for study of, 741

Androgen metabolism, in rheumatoid spondylitis, 322

Anemia

aplastic, and polymyositis, 275-281 iron deficiency, in rheumatoid arthritis,

sickle cell, and lupus erythematosus, 443-

Antibodies

anti-amvloid, 299

antinuclear. See Antinuclear factors to DNA in lupus erythematosus, 379-389

effects on tissue culture cells, 323 fluorescent antibody inhibition method,

for antinuclear factors, 339 influenza A, and rheumatoid factor, 348 inhibition of formation by 7S and 19S

antibody, 324 mercaptoethanol resistant, in SLE, antigenically related to gamma 1 M globulin, 341

non-gamma antinuclear globulin and 7S antibody, 748

rheumatoid factor specificity, papain and cysteine affecting, 313

to ribosomes, in lupus erythematosus, 347 Antigenic properties of synthetic polypeptides, 740

Antigens

chondromucoprotein, antigenic sites of,

protein, inhibiting adjuvant arthritis, 337 Anti-Gm substances

production in pregnancy, 309 in rheumatoid arthritis, 110-117 in sera after transfusions, 730

Antinuclear factors

in aged patients, 297

experimental induction of, 349

fluorescent antibody inhibition for classification of, 339

heterogeneity of, in lupus erythematosus and rheumatoid arthritis, 290

immunofluorescence detecting, 119-127. 161-166

in inbred strains of mice, 753

in lupus erythematosus, 119-127, 379-389 in nephritis with SLE, 350 and non-gamma globulin, 748 in synovial fluid, 726

Arthropathy

acromegalic, 65-73

steroid, 758

Ascorbic acid, effect on dermal fibroblasts, 752

Aseptic necrosis, in lupus erythematosus,

Aspirin metabolism and absorption, 350 See also Salicylates

Attitudes of patients concerning arthritis, 425-435

Autoimmune disease

with Hashimoto's disease, 327

homologous disease as model for, 347, 352

Autoimmunity

and emotional stress, 345 and rheumatoid arthritis, 458

Azathioprine

in lupus erythematosus, 329 in rheumatoid arthritis, 735

Bacterial endotoxin, synovial cellular reaction to, 315

Baker's cyst and thrombophlebitis, rheumatoid arthritis, 56-64

Bauer, Walter, 272-274 Bence Jones proteinemia, with lupus erythematosus, 733

Bibliography of history of rheumatic diseases, 75-79

Bleeding, gastrointestinal, from aspirin, and anemia in rheumatoid arthritis, 354

Blood flow, peripheral, in scleroderma, 351 Bone dysplasias, dynamic classification of, 693-707

Bone erosion, rheumatoid, 287, 326

Book reviews

Bone Remodeling Dynamics (Frost), 545 The Care of the Geriatric Patient (Cowdry), 545

The Care of the Rheumatoid Hand (Flatt), 98 The Chemistry of Connective Tissue Book Reviews—(Continued)

(Hall), 282

Constructive Surgery of the Hip (Aufranc), 282

Handbook of Orthopaedic Surgery (Shands et al.), 282

International Review of Connective Tissue Research (Hall, ed.), 546

Principles of Bone Remodeling (Enlow), 545

A Short History of the Gout and the Rheumatic Diseases (Copeman), 722 Surgery of Arthritis (Milch), 722

Braces and splints. See Splinting

Brachialgia, psychological factors in, 670–

Bulge sign, in knees, 318 Bunim, Joseph Jay, 452, 542–544

Calcification

of anterior spinal ligament, rupture of, in rheumatoid spondylitis, 51–54 of intervertebral disc, 306 meniscal, 328

Calcinosis

chondrocalcinosis with rheumatic diseases, 332

with dermatomyositis, 259–269 Calcium, renal clearance of, 732

Calf symptoms, in rheumatoid arthritis, 56–64

Caloric restriction in obesity, and hyperuricemia, 343

Canadian Indians, rheumatic disease in, 311 Cartilage

achondroplasia, 695-702

articular, immunofluorescent studies of, 290

degeneration of, salicylates affecting, 344 interstitial fluid of, 323

osteoarthritic, 398-405

protein synthesis in, aging affecting, 743 Cataract formation, with steroid therapy in

Catecholamines

excretion of

in rheumatoid arthritis, 687-692 in scleroderma, 138-149

rheumatoid arthritis, 286

oxidative deamination of, in scleroderma, 138–149

Ceruloplasmin, in synovial fluid, 334 Cervical spine. See Vertebral column Charcot's knee, stayphylococcus arthritis in, 327

Chelation therapy

in calcinosis with dermatomyositis, 259-

269

in rheumatic disorders, 99

Chemotaxis of leukocytes, colchicine affecting, 297

Childhood

rheumatoid arthritis in. See Juvenile rheumatoid arthritis scleroderma in. 320

Chloroquine

action on lysosomes, 759, 760 binding to melanin, 337 effect on sulfhydryl group, 193–199 and inhibition of DNA and RNA polymerase reactions, 302

metabolic studies of, 328

ocular toxicity of, 353 Chlorprothixene, uricosuric effect of, 737 Chondrocalcinosis, rheumatic diseases with,

Chondromucoprotein

antigenicity of, 323, 341

enzymatic degradation of, 398-405

Chromosome studies, in lupus erythematosus, 307

Chrysotherapy. See Gold

Clark, William S., 547

Classification of arthritis and rheumatism, 93–96

Coagulation, and metabolism of adenosine nucleotides in platelets, 741

Colchicine

and chemotactic migration of leukocytes, 297

and sols and gels, 325

Colitis, ulcerative, spondylitis with, 338 Collagen

animal, immunologic relationships among, 750

insoluble, characterization of, 322 skin, tensile strength of, 330 synthetic polypeptides resembling, 740

Complement Complement

Complement

hemolytic, in immunological tissue injury, 744
in rheumatoid joint effusions, 308
serum, in nephritis with SLE, 350
synovial fluid, in rheumatoid arthritis, 308,

Computers

749

analysis of lupus erythematosus cases, 305 analysis of serum ultracentrifuge results,

data analysis system for arthritis research, 735

program for study of oral analgesics, 741

Copper in synovial fluid, in rheumatoid arthritis, 334

Coronary heart disease, and hyperuricemia and gouty arthritis, 312

Corticosteroids. See Steroid therapy

Costo-vertebral arthritis, 228-240 Cricothyroid joint, tophus near, in gout, 742

Cryoglobulins, in lupus erythematosus, 321 Crystals

microcrystal-induced arthritis, 359-367, 746

urate, in gout, 534-540

Cyst, Baker's, and thrombophlebitis, and rheumatoid arthritis, 56-64

ferricyanide reduction by, chloroquine affecting, 193-199

and rheumatoid factor antibody specificity.

Cystitis, and arthritis, 220-226

Cytoplasmic inclusions in leukocytes, in rheumatoid arthritis, 760

Deamination, oxidative of catecholamines, in scleroderma, 138-149

Dehydrogenase, lactic acid

in muscle, in ankylosing spondylitis, 346 in synovial fluid and serum, in rheumatic diseases, 490-499

Deoxyribonucleic acid

antibody to, in lupus erythematosus, 379-

polymerase activity, chloroquine affecting, 302

Dermatomyositis

and aplastic anemia, 275-281 and blood content of inositol, 726 with calcinosis, 259-269

steroid therapy in, 351

steroid therapy in, intermittent, 294 Diabetes, and gout, 318

Diabetogenic effect of hydrochlorothiazide,

Diazoxide, effects on urate excretion, 349 Dihydrotachysterol, progeria-like syndrome from, 755

Dimethyl sulfoxide

in connective tissue disease, 294, 725 in rheumatic diseases, 340

Disability, evaluation of, 550-567, 570-572 Dislocation of cervical spine, in rheumatoid arthritis, 308

Disulfide exchange in serum proteins, in rheumatoid arthritis, 736

Drug-induced lupus erythematosus, 285, 684-686

Dysplastic skeletal diseases, classification of, 693-707

Elastin, enzymatic digestion of, 325 Electron microscopy

of cytoplasmic inclusions in leukocytes, 760

of developing chick interphalangeal joint,

of rheumatoid synovial membrane, 335 of rice bodies from rheumatoid patients, 285

of skin, in lupus erythematosus and rheumatoid arthritis, 286

Emotions, immunity and disease, 345 Endotoxin, bacterial, synovial cellular reaction to, 315

Environmental factors, in antinuclear factor development, 753

Enzymatic degradation of chondromucoprotein, 398-405

Eosin-latex test for rheumatoid factor, 723 Epidemiology of rheumatoid arthritis in Israel, 153-159

Epinephrine excretion

in rheumatoid arthritis, 687-692

in scleroderma, 138-149

Epithelial mucins, properties of, 727 Erosion of bone, rheumatoid, 287, 326 Erythrocytes

agglutinins in eluates in rheumatoid arthritis, 739

sheep, formalinized, in modification of Waaler-Rose test, 1-6

survival in rheumatoid arthritis, 481-489 Estrogen suppression of adjuvant arthritis,

Ethylenediamine tetra-acetic acid (EDTA) in calcinosis with dermatomyositis, 259-

in rheumatic disorders, 99

Etiology of rheumatoid arthritis, 455-464 Evaluation of disability, 550-567, 570-572 Exercise therapy, 601-613

Experimental arthritis

from intra-articular papain, 211-219 nerve section and bone trauma in, 303 Experimental models in rheumatoid disease. 80-85

Fasting

in obesity, and hyperuricemia, 343 and uric acid excretion, 313

Feet, radiography of, in rheumatoid arthritis, 292

Ferricyanide, reduction by cysteine, chloro-

Ferricyanide—(Continued)
quine affecting, 193–199

Fibroblasts, dermal, ascorbic acid affecting, 752

Finger flexors, in rheumatoid deformities, 467–479

Fluorescence of joint fluid, after tetracycline, 306

Fluorescent antibody inhibition method, for antinuclear factors, 339

See also Immunofluorescent studies Fractures of hip, and osteoporosis, 293

Gas diffusion, pulmonary, in rheumatoid arthritis, 304

Gastrointestinal bleeding, from aspirin, and anemia in rheumatoid arthritis, 354 Genetic factors in rheumatoid arthritis, 462–

Genitourinary infection, and arthritis, 220-226

Globulin

anti-Gm agglutinins in sera after transfusions, 730

antinuclear. See Antinuclear factors cryoglobulins in lupus erythematosus, 321 gamma globulin

amma globulin
agammaglobulinemia, 309
association with amyloid, 751
autoinhibitory substances in, 336
configuration of, 756
gamma-1 globulin levels in rheumatic

fever, 128-136 infusions of, and rheumatoid factor titers, 352

mercaptoethanol resistant antibodies in SLE antigenically related to gamma 1 M globulins, 341

polymer type heterogenity of γ_{1A} -globulin, 351

reaction of human and rabbit anti-gamma-globulin factors, 368-377

relatives of patients with hypogammaglobulinemia, 759

rheumatoid factor-gamma globulin interaction, 295

and rheumatoid factors, 738

7S gamma globulins in H chain disease, 330

specificity of rheumatoid factors for sites on L-chains of, 353

urinary, 350, 757 non-gamma antinuclear globulin and its 7S antibody, 748

serum alpha globulin and pathologic hyaluronateprotein, 751

Glucose tolerance, hydrochlorothiazide affecting, 292

Glutamic-oxalacetic transaminase, in synovial fluid and serum, in rheumatic disease, 490–499

Glycolipids, in connective tissue during inflammation, 728

Gold

distribution and excretion of, 753 in kidney, D-penicillamine affecting, 406– 411

therapy in rheumatoid arthritis excretion of labelled gold, 319 and marrow function, 304

Gonococcal arthritis, 220-226

Gout

allopurinol affecting uric acid excretion in, 316

and diabetes, 318

dimethyl sulfoxide in, 294, 340

hydrochlorothiazide in, 292 in Marianas Islands, 296

progress in research, 534-540

pseudogout syndrome, 328

and renal clearance of calcium and phosphorus, 732

sols, gels and colchicine in, 325

tophus near cricothyroid joint, 742

uric acid excretion and renal function in, 302

Gouty arthritis, hyperuricemia in, and coronary heart disease, 312

Grafts. See Transplants

Granulocyte turnover, in rheumatoid synovial effusions, 315

Hand, rheumatoid

bone erosion in, 326

distal interphalangeal joints in, 310

flexor tendons in, 467-479

radiography of, 292

surgery in, 329, 342, 568-584

tendons in, 334

Hashimoto's disease, 327

Hearing, in salicylate intoxication, 333

Heart

coronary disease, and hyperuricemia and gouty arthritis, 312

in homologous disease, 347

Hemochromatosis, and arthritis, 41-49

Hemophilia, rheumatic manifestations of, 734

Hip

arthritic pain in, sympathetic denervation for, 314

evaluation of function, 574

Hip—(Continued)

fractures of, and osteoporosis, 293 osteoarthritis of, therapy of, 320 in rheumatoid arthritis, 732

Histamine, in synovial membrane, 749

Homologous disease

cardiac and renal changes in, 347 serologic studies in, 352

Humeroscapular periarthritis, psychological factors in, 670-683

Humoral factors in rheumatoid arthritis, 295 Hyaluronateprotein, pathologic, 751

Hyaluronic acid viscosity, ceruloplasmin affecting, 334

Hydralazine

and protein denaturation, 736 syndrome from, and lupus diathesis, 285 Hydrochlorothiazide, diabetogenic effect of, 292

3-Hydroxyanthranilic acid excretion in rheumatic disease, 662–669 and protein denaturation, 736

Hydroxychloroquine, metabolic studies of, 328

Hydroxykynurenine excretion in rheumatic disease, 201–209, 662–669

4-Hydroxypyrazolo (3,4-d)-pyrimidine, effects on uric acid production, 754

Hyperuricemia. See Uric acid

Immunity

and emotions and disease, 345 transplantation, 87-90

See also Autoimmunity

Immunofluorescent studies of articular cartilage, 290

to detect antinuclear factors, 119–126, 161–166

of skin lesions in SLE, 348

Immunoglobulins

in relatives of patients with hypogammaglobulinemia, 759

in rheumatic fever, 128-136

Immunologic competence, and lymphocyte activity, 303

Immunology

and adjuvant arthritis, 654–661 autoimmune disorders with Hashimoto's disease, 327

See also Autoimmune disease complement role in tissue injury, 744 reactivity of thymic autografts, 755 relationships among animal collagens, 750 and rheumatoid arthritis, 458–460

Imuran, See Azathioprine

Inclusion body, rheumatoid, and antinuclear

factors in synovial fluid, 726

Paclusion-body cells, in synovial fluid, 288
Inclusions, cytoplasmic, in leukocytes, in rheumatoid arthritis, 760

Indians, hyperuricemia in, genetics of, 335 Indomethacin

computer program for study of, 741 pharmacologic effects of, 340

in rheumatic diseases, 340 in rheumatoid arthritis, 300

evaluation of, 345 in rheumatoid spondylitis, 345

Influenza A virus, rheumatoid factor with, 348

Inositol, blood content of, in dermatomyositis, 726

Interphalangeal joints

of developing chick, ultrastructure of, 729 distal, in rheumatoid hand, 310

Interstitial fluid of cartilage, 323

Iron deficiency anemia, in rheumatoid arthritis, 354

Isohemagglutinin deficiency in relatives of rheumatoid patients, 391–397 Israel, epidemiology of rheumatoid arthritis

in, 153–159

Joints

evaluation of function, 551–553, 570–572 infections from pleuropneumonia-like organisms, 437–442

intra-articular Thio-tepa, 337, 355

microcrystalline-induced inflammation in, 359–367, 746

rheumatoid inflammation, pathogenesis of, 314

See also Synovial fluid

Juvenile rheumatoid arthritis

intermittent steroid therapy in, 413-421 monarticular, 298

psychological study in, 301 rheumatoid factor tests in, 298

Kashin-Beck disease, 29-39

Kellgren's syndrome with knee joint fluid analysis, 756

Ketosis, and uric acid excretion, 313

Kidney

function in gout, 302 gold in, D-penicillamine affecting, 406– 411

in homologous disease, 347

homotransplantation of, rheumatic disease after, 739

nephritis with lupus erythematosus, 350 renography in lupus erythematosus, 730

Kiev, rheumatology in, 631–632 Kinin-peptide, in synovial effusions, 311

calcified menisci, 328 exercise therapy for, 605-610

joint fluid analysis in Kellgren's syndrome, 756

small effusions of, 318 splinting of, 586–591

staphylococcus arthritis in Charcot's knee, 327

surgery of, 568-584

unstable, in rheumatoid arthritis, 287 Kynurenic acid excretion, in rheumatic dis-

ease, 662–669 Kynurenine excretion

in connective tissue diseases, 291 pyridoxine affecting, 319 in rheumatic disease, 662–669 in rheumatoid arthritis, 201–209, 643

Lactic acid dehydrogenase

in muscle, in ankylosing spondylitis, 346 in synovial fluid and serum, in rheumatic diseases, 490–499

Latex tests

in aged patients, 297 and anti-Gm substances, 110–117 eosin-latex test for rheumatoid factor, 723 in rheumatoid arthritis, 8–16, 296 Leningrad, rheumatology in, 630–631

Leukocytes

chemotactic migration of, colchicine affecting, 297

cytoplasmic inclusions in, in rheumatoid arthritis, 760 polymorphonuclear, interaction with cry-

stals, 746
Ligament repair of unstable knee, in rheu-

matoid arthritis, 287

Literature analysis project of American
Rheumatism Association, 615–622

Liver diseases, with lupus erythematosus cell phenomenon, 285

Lupus diathesis, 684-686

and hydralazine syndrome, 285

Lupus erythematosus antibody to DNA in, 379–389

antibody to ribosomes in, 347 antinuclear factor in, 119-127

heterogeneity of, 290 aseptic necrosis in, 709–721

azathioprine in, 329
Bence Jones proteinemia with, 733
cell phenomenon

hepatic disease with, 285

in rheumatoid arthritis, 293 chromosome studies in, 307

computer analysis of 520 cases, 305 cryoglobulins in, 321

drug-induced, 285, 684-686

electron microscopy of skin specimens, 286

and isolation of PPLO, 291

and mercaptoethanol resistant antibodies antigenically related to gamma 1 M globulins, 341

nephritis with, findings in, 350

prognosis of, 305

racial and social factors in, 343

renography in, 730

respiratory dysfunction in, 317

and sickle cell anemia, 443-449

skin lesions in, immunofluorescent study of, 348

steroid therapy in, 502-511

tryptophan metabolism in, 662-669

Lymphocytes

anti-lymphocyte serum, effects of, 731 and immunologic competence, 303 polysaccharides on, 310

Lysosomal acid phosphatase, and antibody effects on tissue culture cells, 323

Lysosomes

chloroquine affecting, 759, 760 steroids affecting, 759

Marianas Island, hyperuricemia in, 296 Marie-Strumpell spondylitis, in Canadian Indians, 311

Marrow function, gold therapy affecting, 304 Mechlorethamine hydrochloride, in adjuvant arthritis, 654–661

Melanin, chloroquine binding to, 337 Meningococcal arthritis, 241-255

Meniscal calcification, 328

Mercaptoethanol resistant antibodies in SLE, antigenically related to gamma 1 M globulins, 341

6-Mercaptopurine

in adjuvant arthritis, 654-661 in rheumatoid arthritis, 735

Metacarpophalangeal joint, rheumatoid, 467–479

Metanephrine, levels of, in scleroderma, 138–149

Methotrexate, in adjuvant arthritis, 654–661 Microbial agents in rheumatoid arthritis, 460–462

Microcrystalline-induced inflammation, 359–367, 746

Milk ingestion by rheumatoid arthritis pa-

I

Milk ingestion—(Continued) tients, 752

Mink disease, Aleutian, 521-533

Monoamine oxidase activity, in scleroderma, 138–149

Mortality from rheumatoid arthritis, 728 Moscow, rheumatology in, 624-630

Mucins, epithelial, properties of, 727

Mucopolysaccharides, in rachitic tissue, 317 Mycobacterial adjuvant disease. See Adjuvant disease

Mycoplasma, See Pleuropneumonia-like organisms

Myeloma proteins, in H chain disease, 330

Necrosis, aseptic, in lupus erythematosus, 709–721

Necrotizing factor in sera, 331 and permeability factor, 332

Nephritis, lupus erythematosus with, 350

section of, in experimental arthritis, 303 sympathetic denervation for pain relief,

Neuropathy

of knee, and staphylococcus arthritis, 327 rheumatoid, 312

Neutrophil function, in rheumatoid joint inflammation, 748

New York Rheumatism Association, 167–170 Nomenclature of arthritis and rheumatism,

Norepinephrine excretion

in rheumatoid arthritis, 687-692

in scleroderma, 138-149

Normetanephrine, levels of, in scleroderma, 138-149

Nucleoprotein antibodies. See Antinuclear factors

Obesity, caloric restriction in, and hyperuricemia, 343

Ochronosis, experimental, 292

Ocular lesions from chloroquine, 353

Orthopedic measures in rheumatoid arthritis, 549-613, 727

evaluation of disability, 550-567, 570-572 exercise therapy, 601-613

splinting, 342, 585-600

splinting, 342, 585–60 surgery, 568–584

See also Surgery

Osteoarthritis

articular cartilage in, immunofluorescent studies of, 290

cartilage destruction in, 398-405 dimethyl sulfoxide in, 294, 340 of hip, therapy of, 320

Kashin-Beck disease, 29-39

salicylate levels in serum after therapy, 750

Osteolysis, massive, and cervical spine subluxation, 759

Osteoporosis

and hip fractures, 293

of rheumatoid arthritis, 732

Oxidative deamination of catecholamines, in scleroderma, 138–149

Pain, relief of, with sympathetic denervation, 314

Papain

intra-articular, inducing arthritis, 211–219 and rheumatoid factor antibody specificity, 313

Parabiotic rats, polyarthritis in, 758

Patients' attitudes on arthritis, 425–435 D-Penicillamine, effects on gold in kidney, 406–411

Peptides

kinin-peptide in synovial effusions, 311 synthetic polypeptides, antigenic properties of, 740

Periarthritis, psychologic factors in, 670–683 Permeability factor, and necrotizing factor, 332

Personality patterns in rheumatoid arthritis, 18-27, 354, 458

and response to therapy, 331

Phosphatase, acid, and antibody effects on tissue culture cells, 323

Phosphorus, renal clearance of, 732

Platelets, metabolism of adenosine nucleotides in, 741

Pleuropneumonia-like organisms (PPLO) isolation of, 291

and joint infections, 437-442

and rheumatoid arthritis, 460-462

Polley, Howard F., 451

Polyarthritis

adjuvant-induced, and immune responses, 654-661

in parabiotic rats, 758

Polymyositis. See Dermatomyositis

Polypeptides, synthetic, antigenic properties of, 740

Polysaccharides

on lymphocytes, 310

in rachitic tissue, 317

sulfated, fats and distribution of, 757

Potassium levels, in rheumatoid arthritis, 321 Predisposition to rheumatic disease, 684–686

user led in Thesaurus misses) Pregnancy, anti-Gm activity in, 309 Progeria-like syndrome, experimental, 755 Protein

antigens inhibiting adjuvant arthritis, 337 Bence-Jones, with lupus erythematosus, 733

collagen-like, in plasma, 742 denaturation of, drugs affecting, 736 hidden intermediate S value proteins, 737 local response to foreign and self proteins, 744

myeloma, in H chain disease, 330 nucleoprotein antibodies. See Antinuclear factors

pathologic hyaluronateprotein, 751 serum

in aged, 297 disulfide exchange in, with rheumatoid arthritis, 736

sulfhydryl content in disorders, 743 stabilizing agents, 331

synthesis in articular cartilage, aging affecting, 743

See also Globulin Pseudogout syndrome, 328

Pseudoxanthoma elasticum, skin in, 325 Psoriasis, spondylitis with, 338

Psychological factors

in brachialgia and periarthritis, 670–683 in evaluation of disability, 553–555 in rheumatoid arthritis, 18–27, 354, 458 in children, 301

and response to therapy, 331

Puerto Rico, rheumatoid arthritis in, 171–175 Pulmonary system dysfunction in lupus erythematosus, 317

gas diffusion in rheumatoid arthritis, 304
Pyrazinamide, inhibiting tubular secretion
of uric acid. 303

4-Pyridoxic acid excretion, in rheumatoid arthritis, 201–209, 636–653

Pyridoxine

and tryptophan metabolism in rheumatoid arthritis, 201–209, 319 urinary excretion of, in rheumatoid arthritis, 636–653

Rachitic tissue, biochemical composition of, 317

Racial variations in serum uric acid, 730 Radiation, total body, in adjuvant arthritis, 654–661

Radiography

in rheumatoid arthritis, 292 of cervical spine, 727 of hip, 732 of spondylitis with other diseases, 338 Reiter's syndrome and isolation of PPLO, 291

and isolation of PPLO, 291 and rheumatoid arthritis, 177–188 spondylitis with, 338

Relatadex data analysis system for arthritis research, 735

Renography in lupus erythematosus, 730 Respiratory dysfunction, in lupus erythematosus, 317

Resting splints, silicone foam, 342

Reticuloendothelial system, in rheumatoid arthritis, 331

Retinopathy, from chloroquine, 353

Rheumatic disease

albumin alterations in, 747
antinuclear factors in synovial fluid, 726
bibliography from 1940–1962, 75–79
in Canadian Indians, 311
chondrocalcinosis with, 332
and complement activity in synovial fluid,

distal interphalangeal joints in, 310 with hemophilia, 734 indomethacin in. See Indomethacin

lactic acid dehydrogenase and transaminase determinations in, 490–499 orthopedic measures in, 549–613, 727

predisposition to, 684–686 properties of antirheumatic agents, 331 after renal homotransplantation, 739 serum sulfhydryl concentrations in, 324 Thio-tepa in, intra-articular, 337, 355 tryptophan metabolism in, 662–669

Rheumatic fever gamma-1 globulin levels in, 128-136

recurrent episodes of, 307 Rheumatoid arthritis

and agglutinins from erythrocyte eluates, 739

amopyroquin in, 289

anti-Gm substances in, 110–117 antinuclear factors in, heterogeneity of, 290

attitudes of patients, 425-435 azathioprine in, 735

and Baker's cyst and thrombophlebitis, 56-64

bone erosion in, 287, 326 in Canadian Indians, 311

catecholamine excretion in, 687–692 and ceruloplasmin in synovial fluid, 334 cervical spine in, 308, 326, 727

chelating agents in, 99 chloroquine in, effects of, 193-199 complement activity in, 308, 749 Rheumatoid arthritis-(Continued) criteria for diagnosis of, 745 and cytoplasmic inclusions in leukocytes, 760 dimethyl sulfoxide in, 294, 340 and disulfide exchange in serum proteins, electron microscopy of skin specimens, 286 epidemiology in Israel, 153-159 erythrocyte survival in, 481-489 etiological considerations, 455-464 evaluation of disability, 550-567 exercise therapy, 601-613 experimental models in, 80-85 genetic factors in, 462-463 gold therapy in excretion of labelled gold, 319 and marrow function, 304 See also Gold hand in. See Hand, rheumatoid hip joint in, 732 See also Hip humoral factors in, 295 hypoalbuminemia in, 740 immunologic aspects, 458-460 indomethacin in. See Indomethacin infusions of plasma or gamma globulin in, 352 iron deficiency anemia in, 354 isohemagglutinin deficiency in relatives of patients, 391-397 and isolation of PPLO, 291 juvenile. See Juvenile rheumatoid arthritis kypurenine excretion in, 201-209, 291, 643 latex fixation test in, 8-16 See also Latex tests LE phenomenon in, 293 6-mercaptopurine in, 735 metabolic abnormalities in, 457 metacarpophalangeal joint deformity, 467-479 microbial agents in, 460-462 milk ingestion by patients, 752 mortality from, 728 neuropathy in, 312 neutrophil function in, 748 orthopedic measures in, 549-613, 727 osteoporosis of, 732 and particles in synovial fluid, 743 pathogenesis of joint inflammation, 314 personality patterns in, 18-27, 331, 354,

plasma and serum viscosity in, 344

prevalence in Puerto Rico, 171-175

potassium levels in, 321

psychological factors in, 18-27, 301, 331, 354, 458 pulmonary gas diffusion in, 304 pyridoxine affecting tryptophan metabolism in, 201-209, 319 pyridoxine excretion in, 636-653 and Reiter's syndrome, 177-188 response to therapy, and personality factors, 331 reticuloendothelial system in, 331 rice bodies from patients, 285 roentgen changes in 292 salicylates in, 309 See also Salicylates splinting in, 342, 585-600 steroid therapy and cataract formation, 286 intermittent, 294, 413-421 See also Steroid therapy surgery in, 568-584 See also Surgery Thio-tepa in, intra-articular, 337, 355 tryptophan metabolism in, 319, 662-669 tryptophan metabolite excretion in, 201-209, 754 unstable knee in, ligament repair of, 287 Waaler-Rose test in, modification of, 1-6 Rheumatoid factor with antibody response to viral disease, 348 antibody specificity of, papain and cysteine affecting, 313 as autoantibody or isoantibody, 724 autoinhibition of agglutination rectivity in, 336 and coating of latex particles, 296 eosin-latex test for, 723 gamma_{1A} and gamma₂, 738 and gamma globulin interaction, 295 with hidden autospecificity, 725 and infusions of plasma or gamma globulin, 352 in normal population, 513-519 specificity for sites on L-chains of gamma globulin, 353 tests in juvenile rheumatoid arthritis, 298 Rheumatoid spondylitis. See Spondylitis Rheumatology in the U.S.S.R., 623-635 Ribonucleic acid polymerase activity, chloroquine affecting, 302 Ribosomes, antibody to, in lupus erythematosus, 347 Rice bodies, from rheumatoid patients, 285 Rupture of calcified anterior spinal ligament, 51 - 59Russia, rheumatology in, 623-635

Saccharides

mucopolysaccharides in rachitic tissue, 317 polysaccharides. See Polysaccharides

Salicylates

absorption and metabolism of aspirin, 350 bleeding from, and anemia in rheumatoid arthritis, 354

computer program for study of, 741 effect on cartilage degeneration, 344 intoxication from, hearing after, 333

in rheumatoid arthritis, 309 serum levels of, after therapy with, 750 simultaneous concentrations in body fluids, in rheumatoid arthritis, 103–109

Scleroderma

chelating agents in, 99 in childhood, 320

dimethyl sulfoxide in, 294

and oxidative deamination of catecholamines, 138-149

peripheral blood flow in, 351

steroid therapy in, intermittent, 294 L-thyroxine in, 734

tryptophan metabolism in, 662-669 Sclerosis, systemic, See Scleroderma

Shoulder pain, psychological factors in, 670-683

Sickle cell anemia, and lupus erythematosus, 443–449

Silicone foam resting splints, 342

ascorbic acid affecting dermal fibroblasts, 752

electron microscopy of, in lupus erythematosus and rheumatoid arthritis, 286 immunofluorescent study in SLE, 348 in pseudoxanthoma elasticum, 325 tensile strength of collagens, 330

South America, serum uric acid studies in, 747

Soviet Russia, rheumatology in, 623–635 Spinal ligament, anterior, calcified, rupture of, 51–59

Spine. See Vertebral column

Splinting

aims of, 586-589 evaluation of, 585-600

with silicone foam, 342

Spondylitis

ankylosing, muscle lactate dehydrogenase in, 346

diseases with, studies of, 338

Marie-Strumpell, in Canadian Indians, 311

androgen metabolism in, 322 indomethacin in, 345

kynurenine excretion in, 291 and ruputure of calcified anterior spinal ligament, 51-54

Spondylo-epiphyseal dysplasia, 702-706

Staphylocoecus arthritis, in Charcot's knee, 327

Starvation, and hyperuricemia, 343

See also Fasting

Steroid therapy

action on lysosomes, 759 arthropathy with, 758

and cataract formation, in rheumatoid arthritis, 286

cortisol affecting connective tissue, 738 intermittent administration, 294

in juvenile rheumatoid arthritis, 413-421

intrasynovial, inflammatory reaction from, 359-367

in lupus erythematosus, 502-511 and aseptic necrosis, 709-721

in polymyositis, 351

Sukhumi, rheumatology in, 632

Sulfhydryl, serum

chloroquine affecting, 193-199 protein content in disorders, 743

in rheumatoid disease, 324

Suppurative arthritis, nongonococcal, 288 Surgery in rheumatoid arthritis, 568–584

of rheumatoid hand, 329, 342

Surinam, uric acid serum levels in, 747 Sympathetic denervation, for arthritic hip pain, 314

Synovectomy, evaluation of results of, 568-584

Synovial cellular reaction to bacterial endotoxin, 315

Synovial fluid

antinuclear factors in, 726

ceruloplasmin in, 334

complement activity in, in rheumatic diseases, 308, 749

enzymes in, in rheumatic diseases, 490-499

fluorescence of, after tetracycline, 306 histamine in, 749

hyaluronate and protein in, 751

inclusion-body cells in, 288

kinin-peptide in, 311

rheumatoid

cellular particles in, 743

granulocyte turnover in, 315

salicylates in, in rheumatoid arthritis, 103-

small effusions of knee, 318

Synovial membrane

Synovial membrane—(Continued) histamine in, 749 rheumatoid, electron microscopy of, 335

Tendons

aging in, 733

in rheumatoid hand, 334

Tensile strength of skin collagen, 330

Tetracycline, and fluorescence of joint fluid, 306

Thio-tepa, intra-articular, 337, 355

Thrombin formation, and metabolism of adenosine nucleotides in platelets, 741

Thrombophlebitis and Baker's cyst, and rheumatoid arthritis, 56-64

Thymic autografts, immunological reactivity of, 755

Thyroid, tophus near cricothyroid joint in gout, 742

Thyroiditis, Hashimoto's, 327

L-Thyroxine, in scleroderma, 734

Tissue explants, amyloid production in, 301 Tophus near cricothyroid joint in gout, 742 Transaminase, glutamic-oxalacetic, in syn-

ovial fluid and serum in rheumatic diseases, 490-499

Transfusions, blood, and isoprecipitins and anti-Gm agglutinins in sera, 730

Transplants

kidney, rheumatic disease after, 739 thymic autografts, immunological reactivity of, 755

transplantation immunity, 87-90

Trauma

effects in experimental arthritis, 303 and rupture of calcified anterior spinal ligament, 51–59

Tryptophan metabolism in rheumatic disease, 662–669

pyridoxine affecting, 319, 636-653

Tryptophan metabolites

excretion in connective tissue diseases, 291 excretion in rheumatoid arthritis, 201–209, 457, 754

Tuberculin hypersensitivity, and arthritis, 654–661

L-Tyrosine, experimental ochronosis from, 292

Ultracentrifuge patterns, computer analysis of, 737

Urethritis, and arthritis, 220-226

Uric acid

determinations of, automated, 336 excretion of

allopurinol affecting, 316 diazoxide affecting, 349 fasting and ketosis affecting, 313 in gout, 302

hyperuricemia

and amino acids, 319 genetics of, in Indians, 335

in gout, 534–540

and gouty arthritis, and coronary heart disease, 312

in Marianas Islands, 296

with obesity and caloric restriction, 343 labelled, stop flow analysis of, 303 metabolism in Wilson's disease, 346

retaining effects of hydrochlorothiazide, 292

serum

chloroprothixene affecting, 737
racial variations in, 730
in Surinam population, 747
xanthine oxidase inhibitor affecting, 754
Urov disease, 29–39

Vanillylmandelic acid, urinary, in scleroderma, 138–149

Vertebral column

in arthritis, 228-240

cervical spine in rheumatoid arthritis, 308, 326, 727

intervertebral disc calcification, 306 subluxation of cervical spine and massive osteolysis, 759

Viral disease, rheumatoid factor with, 348 Viscosity of plasma and serum, in rheumatoid arthritis, 344

Waaler-Rose test

and anti-Gm substances, 110-117 modification of 1-6

standardization of, 299

Wilson's disease, uric acid metabolism in, 346

Wrist

bone erosion in, in rheumatoid arthritis, 326

radiography of, in rheumatoid arthritis, 292

Xanthine oxidase inhibitor, and uric acid production, 754

Xanthurenic acid excretion pyridoxine affecting, 319

in rheumatic disease, 662-669

Zyloprim, effects on uric acid production, 754

